BioNTech SE (Nasdaq: BNTX), a Mainz, Germany-based immunotherapy company, acquired InstaDeep Ltd., a London, Uk-based technology company in the field of artificial intelligence and machine learning.
The transaction includes a total upfront consideration of approximately £362 million in cash and BioNTech shares to acquire 100% of the remaining InstaDeep shares, excluding the shares already owned by BioNTech.
With the acquisition, expected to close in the first half of 2023, subject to customary closing conditions and regulatory approvals, BioNTech will build capabilities in AI-driven drug discovery and development of next-generation immunotherapies and vaccines to address diseases with high unmet medical need. Upon closing, InstaDeep will operate as a UK-based global subsidiary of BioNTech. The company is expected to add approximately 240 professionals and a global network of research partners in the fields of artificial intelligence, machine learning and data science based in the world’s leading global technology hubs.
Led by CEO Karim Beguir, InstaDeep offers a host of AI solutions, ranging from optimized pattern-recognition, GPU-accelerated insights, to self-learning decision making systems. The company harnesses reinforcement learning to create systems that can make decisions on their own, based on their own autonomous training. With Nvidia’s DGX-1, InstaDeep can help to achieve the computing power to solve even the most intensive AI problems.
Led by CEO Ugur Sahin, Biopharmaceutical New Technologies is an immunotherapy company developing therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
FinSMEs
12/01/2023